CDER Announces Guidance Documents for 2018
The FDA center released its list of planned guidance documents for the rest of the year.
FDA’s Center for Drug Evaluation and Research (CDER) released its planned 2018 agenda for guidance documents on Jan. 19, 2018. The center plans on publishing approximately 107 guidance documents this year discussing topics ranging from advertising, clinical, development, safety, approval submissions, generics, labeling, and more.
Specific topics to be addressed by CDER this year include biomarker qualification, postmarket safety reporting, electronic regulatory submissions, drug master files, CMC approval requirements, opioid products, rare diseases, and user fees.
The agency also has a variety of guidance documents addressing generic drugs and abbreviated new drug applications. Exclusivity, topical patches, and bioequivalence studies are some of the generic drug topics discussed.
The full list of planned guidance documents can be found on FDA’s website.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
